Foresite Capital Management II 13F filings and top holdings and stakes

Foresite Capital Management II as of Dec. 31, 2020

Portfolio Holdings for Foresite Capital Management II

Foresite Capital Management II holds 4 positions in its portfolio as reported in the December 2020 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Share Count	Share Price
10x Genomics Class A Common (TXG)	93.6	$355M	2.5M	141.60
Epizyme	2.9	$11M	1.0M	10.86
Novavax (NVAX)	2.0	$7.5M	67k	111.51
Acceleron Pharma	1.5	$5.9M	46k	127.93

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z